PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study

Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up of a prospective multicenter cohort study Publication: Breast Cancer Research and Treatment 2024 Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W. G. van der Velden, Read More

Identification of Racial Disparities (ESMO 2024)

Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Publication: ASCO 2024, Abstract #534 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Background: Black women in Read More